Company Profile (AI Text)
Name: Mahzi Therapeutics
Canonical URL: https://wefunder.com/mahzi.therapeutics
Updated at: 2026-06-11T23:52:05Z

Tagline: Advancing precision therapies for rare neurodevelopmental diseases

Key claims:
- Total raised on Wefunder: 0 | citation: https://wefunder.com/mahzi.therapeutics#claim-total-raised
- Total investors: 0 | citation: https://wefunder.com/mahzi.therapeutics#claim-total-investors

Verified facts:
- Total raised on Wefunder: 0 | observed_at: 2026-06-11T23:52:05Z | expires_at: 2026-06-12T23:52:05Z
- Total investors: 0 | observed_at: 2026-06-11T23:52:05Z | expires_at: 2026-06-12T23:52:05Z

Computed metrics:
- total_amount_raised: 0
- total_investors: 0
- team_size: 7
- featured_investor_count: 1
- faq_count: 0
- recent_post_count: 0

Quick facts:
- $60M raised from leading VCs: Venrock, HealthCap, Droia Ventures & HBM Partners | citation: https://wefunder.com/mahzi.therapeutics#claim-fact-1
- $16M in non-dilutive grant awards from the California Institute for Regenerative Medicine | citation: https://wefunder.com/mahzi.therapeutics#claim-fact-2
- Leadership from Stanford, Cambridge, Yale, UC Berkeley & Weizmann Institute | citation: https://wefunder.com/mahzi.therapeutics#claim-fact-3
- Close collaborations with Pitt Hopkins Foundation & many other patient advocacy groups | citation: https://wefunder.com/mahzi.therapeutics#claim-fact-4
- CEO with 20+ years at Merck and rare disease pioneers Genzyme & Ultragenyx | citation: https://wefunder.com/mahzi.therapeutics#claim-fact-5
- Now enrolling patients in first-ever gene therapy clinical trial for Pitt Hopkins Syndrome | citation: https://wefunder.com/mahzi.therapeutics#claim-fact-6
- 800+ rare neurogenetic disorders addressable with our approach; targeting a $16B+ market | citation: https://wefunder.com/mahzi.therapeutics#claim-fact-7
- $200-$600M peak annual revenue projected per indication in pipeline (not guaranteed) | citation: https://wefunder.com/mahzi.therapeutics#claim-fact-8